Pfizer beats revenue estimates, raises profit outlook on cost cuts and smaller-than-feared drop in Covid drug sales

Products You May Like

In this article

Jakub Porzycki | Nurphoto | Getty Images

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.

The company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from its prior guidance of $2.05 to $2.25 per share.

Pfizer reiterated its previous revenue forecast of $58.5 billion and $61.5 billion, which it first outlined in mid-December. 

Here’s what Pfizer reported for the first quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: 82 cents adjusted, it was not immediately clear if it is comparable to the 52 cents expected.
  • Revenue: $14.88 billion vs. $14.01 billion expected.

After a rocky 2023, Wall Street appears to be skeptical about whether Pfizer can turn its business around just yet.

The stock fell roughly 40% in 2023 as demand for Covid treatment Paxlovid and its vaccine against the virus dried up, causing the company to dramatically slash its full-year revenue forecast and record multibillion-dollar charges related to inventory write-offs. Pfizer also disappointed the street with an underwhelming launch of a new RSV shot and a twice-daily weight loss pill that fell short in clinical trials. 

Products You May Like

Articles You May Like

Can Economic Growth Help Solve Our Debt Problem?
How Macy’s, Kohl’s and Nordstrom are chasing Millennial, Gen Z shoppers
Americans are going into debt to buy groceries. Here’s why those balances can be difficult to pay down
Boeing supplier Spirit AeroSystems lays off workers, citing lower plane delivery rates
E.l.f. Beauty posts first $1 billion year, but shares fall on weaker-than-expected guidance

Leave a Reply

Your email address will not be published. Required fields are marked *